Home / Pharmaceuticals / Gout Therapeutics Market By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Colchicine, Corticosteroids, Uric Acid Lowering Agents) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Gout Therapeutics Market By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Colchicine, Corticosteroids, Uric Acid Lowering Agents) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Published: Nov 2017 | Report Code: 58808-11-17

Gout is a complex form of inflammatory arthritis characterized by recurrent attacks of a severe pain and swollen joints. Gout therapeutics market is rapidly growing due to factors such as growing incidence of gout, significant unmet needs, growing treatment awareness, and promising pipeline molecules. The incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors. Favorable reimbursement policies by government agencies and private organizations in developed countries, growing number of obese population and rising treatment compliance are another factors that fueling the market growth of gout therapeutics.

The report titled “Gout therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall gout therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class (non-steroidal anti-inflammatory drugs, colchicine, corticosteroids and uric acid lowering agents) and different geographical regions. Geographically, the global gout therapeutics market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gout therapeutics market. Pipeline analysis of gout therapeutics and global epidemiology of gout has been included in the study. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global gout therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global gout therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global gout therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Gout Therapeutics Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Gout Therapeutics Market Snapshot
2.2 Global Gout Therapeutics Market, by Drug Class
2.3 Global Gout Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Gout Therapeutics Market Analysis
3.1 Global Gout Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Global Epidemiology of Gout
3.5 Competitive Landscape of Key Players in Gout Therapeutics Market
3.6 Top 3 Countries

Chapter 4 Pipeline Analysis of Gout Therapeutics
4.1 Overview
4.2 Pipeline Analysis of Gout Threapeutics

Chapter 5 Global Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
5.1 Overview
5.2 Attractive Investment Proposition: Global Gout Therapeutics Market, by Drug Class, 2016
5.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.4 Colchicine
5.5 Corticosteroids
5.6 Uric Acid Lowering Agents

Chapter 6 Global Gout Therapeutics Market, by Geography, 2015-2025 (US$ Mn)
6.1 Preface
6.2 North America (U.S. & Canada)
6.2.1 North America Gout Therapeutics Market, by Drug Class, 2015- 2025 (US$ Mn)
6.2.2 North America Gout Therapeutics Market, by Country, 2015- 2025 (US$ Mn)
6.2.2.1 United States
6.2.2.2 Canada
6.3 Europe (U.K., Germany & Rest of Europe)
6.3.1 Europe Gout Therapeutics Market, by Drug Class, 2015- 2025 (US$ Mn)
6.3.2 Europe Gout Therapeutics Market, by Country, 2015- 2025 (US$ Mn)
6.3.2.1 United Kingdom
6.3.2.2 Germany
6.3.2.3 Rest of Europe
6.4 Asia Pacific (China, Japan and Rest of APAC)
6.4.1 Asia Pacific Gout Therapeutics Market, by Drug Class, 2015- 2025 (US$ Mn)
6.4.2 Asia Pacific Gout Therapeutics Market, by Country, 2015- 2025 (US$ Mn)
6.4.2.1 China
6.4.2.2 Japan
6.4.2.3 Rest of Asia Pacific
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.5.1 Latin America Gout Therapeutics Market, by Drug Class, 2015- 2025 (US$ Mn)
6.5.2 Latin America Gout Therapeutics Market, by Country, 2015- 2025 (US$ Mn)
6.5.2.1 Brazil
6.5.2.2 Mexico
6.5.2.3 Rest of Latin America
6.6 Middle East and Africa (GCC and Rest of MEA)
6.6.1 Middle East and Africa Gout Therapeutics Market, by Drug Class, 2015- 2025 (US$ Mn)
6.6.2 Middle East and Africa Gout Therapeutics Market, by Country, 2015- 2025 (US$ Mn)
6.6.2.1 GCC
6.6.2.2 Rest of Middle East and Africa

Chapter 7 Company Profiles
7.1 Ardea Biosciences, Inc.
7.2 AstraZeneca plc.
7.3 BioCryst Pharmaceuticals, Inc.
7.4 Cymabay Therapeutics, Inc.
7.5 GlaxoSmithKline plc.
7.6 Horizon Pharma Plc.
7.7 Novartis AG
7.8 Regeneron Pharmaceuticals, Inc.
7.9 Sanofi Aventis
7.10 Savient Pharmaceuticals, Inc.
7.11 Selecta Biosciences, Inc.
7.12 Takeda Pharmaceutical Company Ltd.
7.13 Teijin Pharma Ltd.

List of Tables :

TABLE 1 Market Positioning of Key Players in Global Gout Therapeutics Market
TABLE 2 Top 3 Countries in Global Gout Therapeutics Market
TABLE 3 Global Gout Therapeutics Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 Global Gout Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
TABLE 6 North America Gout Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
TABLE 8 Europe Gout Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Gout Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
TABLE 12 Latin America Gout Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Gout Therapeutics Market, by Drug Class, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Gout Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Ardea Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 AstraZeneca plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 BioCryst Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Cymabay Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Horizon Pharma Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Regeneron Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi Aventis: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Savient Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Selecta Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Takeda Pharmaceutical Company Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 27 Teijin Pharma Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

List of Figures :

FIG. 1 Gout Therapeutics Market: Research Methodology
FIG. 2 Global Gout Therapeutics Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Gout Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Gout Therapeutics Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Gout Therapeutics Market, by Drug Class, 2016
FIG. 6 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market in Gout Therapeutics, 2015 – 2025 (US$ Mn)
FIG. 7 Global Colchicine Market in Gout Therapeutics, 2015 – 2025 (US$ Mn)
FIG. 8 Global Corticosteroids Market in Gout Therapeutics, 2015 – 2025 (US$ Mn)
FIG. 9 Global Uric Acid Lowering Agents Market in Gout Therapeutics, 2015 – 2025 (US$ Mn)

Based on drug classes, the global gout therapeutics market is segmented as follows:  

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Colchicine
  • Corticosteroids
  • Uric Acid Lowering Agents

Gout is a complex form of arthritis characterized by sudden, severe attacks of pain and tenderness in joints. The incidence of gout has increased to a great extent in the past two decades. According to the U.S. Centers for Disease Control and Prevention (CDC) gout affects approximately 4 percent of Americans. Therapeutics not only treat gout symptoms but also prevent future flares and reduce the risk of complications. Colchicine, corticosteroids and NSAIDs such as ibuprofen, naproxen, celecoxib, indomethacin etc. are recommended in treatment of acute gout attack. Currently, NSAIDs are dominating the gout therapeutics market due to its wide availability, lower price and ability to reduce gout pain and inflammation. Combination therapy of uric acid lowering agents is noticed to be widely administered, and it is estimated that it will show significant market growth during the forecast period due to faster onset of action with minimum the adverse effects. Duzallo (lesinurad and allopurinol), approved in 2017 is touted to be a promising drug for gout treatment and Ironwood expected to exceed total annual U.S. peak sales of $300 million. Presence of ideal pipeline molecules such as arhalofenate, bucillamine, levotofisopam, ulodesine, verinurad etc. would assist in achieving significant market growth during forecast period 2017-2025. Due to target specificity and efficacy, demand for biologics is expected to increase in market. At present, approved biologics such as Canakinumab and Krystexxa are driving the growth of gout therapeutics market globally.

Gout Therapeutics Market

For the purpose of this study, the global gout therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Gout Therapeutics Market

The prevalence and incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors. However, the highest prevalence worldwide is reported in Taiwanese, with some estimates of more than 10%. It is studied that, in the base year 2016, North America dominated the gout therapeutics market. United States was largest revenue contributor due to the upsurge in funding by government agencies and private organizations in healthcare system, higher cost of therapeutics and large number of target population with high treatment awareness. According to the Centers for Disease Control and Prevention (CDC), more than 4 percent of population is affected with gout in United States. Expected launch of pipeline molecules such as arhalofenate, bucillamine, levotofisopam, ulodesine, verinurad etc. is expected to assist gout therapeutics market growth in North America. On the other hand, Asia Pacific is estimated to show the fastest market growth over the forecast years due to the rising number of affected population, growing investment of key players with the local manufacturers in the region, and rapidly improving healthcare infrastructure. Furthermore, changing lifestyle pattern, growing rates of smoking & alcohol consumption boost the gout therapeutics market over the forecast period 2017-2025.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients